Table 3 univariate & multivariate analysis to determine the risk factors for mortality among infective C. auris cases
Category | Died n = 30 (100%) | Survived n = 35 (100%) | Univariate | Multivariable | ||
|---|---|---|---|---|---|---|
OR*[95% CI] | P-value | AOR†[95% CI] | P-value | |||
Age group | ||||||
16–35 | 5 (16.7%) | 10 (28.6%) | 1.0 | |||
36–55 | 10 (33.3%) | 10 (28.6%) | 2.0 [0.5–7.9] | 0.32 | ||
56–75 | 13 (43.3%) | 08 (22.9%) | 3.2 [0.8–13] | 0.09 | 4.5 [1.09–18.9] | 0.038 |
76–96 | 02 (6.7%) | 07 (20%) | 0.5 [0.08–3.8] | 0.56 | ||
Location in hospital | ||||||
ICU | 14 (46.7%) | 09 (25.7%) | 3.4 [0.8–13] | 0.07 | 1.2 [0.24–5.8] | 0.81 |
Special Care | 11 (36.7%) | 13 (37.1%) | 1.86 [0.5–7.0] | 0.35 | ||
Ward | 05 (16.7%) | 11 (31.4%) | 1.0 | 0.19 | ||
Outpatient | 0 | 02 (3.1%) | ||||
Diabetes Mellitus | 11 (36.7%) | 07 (20%) | 2.3 [0.7–7.0] | 0.13 | ||
Malignancy | 06 (20%) | 06 (17.6%) | 0.96 [0.20–3.2] | 0.95 | ||
Candidemia | 23 (76.7%) | 15 (42.9%) | 4.3 [1.4–12] | 0.007 | 4.2 [1.09–16.49] | 0.03 |
Early blood clearance (≤72 h) | 02 (18.2%) | 5 (35.7%) | 1.0 | |||
Late blood clearance (> 72 h) | 09 (81.8%) | 9 (64.3%) | 2.5 [0.38–16.42] | 0.34 | ||
No blood clearance | 02 (15.4%) | 0 (0) | ||||
Appropriate antifungal therapy | 23 (76.7%) | 21 (60%) | 2.2 [0.7–6.4] | 0.15 | ||
Early antifungal therapy | 14 (46.7%) | 6 (17.1%) | 4.66 [1.2–17.43] | 0.02 | 0.84 [0.16–4.3] | 0.83 |
Late antifungal therapy | 09 (30%) | 15 (42.9%) | 1.2 [0.3–4.09] | 0.77 | 4.1 [0.94–17.9] | 0.06 |
Source control | 17 (42.5%) | 25 (57.5%) | 0.52 [0.18–1.46] | 0.2 | 0.22 [0.05–0.92] | 0.038 |
Early source control | 07 (41.2%) | 13 (56.5%) | 1.0 | |||
Late source control | 10 (58.8%) | 10 (43.5%) | 1.5 [0.4–5.3] | 0.49 | ||
Co infection with multidrug resistant bacteria | 13 (43.3%) | 09 (25.7%) | 2.2 [0.77–6.2] | 0.13 | 2.7 [0.61–12.6] | 0.18 |